We use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits. If you continue browsing the website, you accept its installation and use as aforementioned. You may modify the settings and obtain more information here

Grifols Movaco, S.A.

Grifols' Spanish Distribution Subsidiary

GRIFOLS MOVACO, S.A. is a GRIFOLS, S.A. subsidiary dedicated to the storage, commercialization and distribution of products manufactured by the group's various businesses, as well as those produced by several third-party companies. In addition to these services, the company also provides after-sales support to purchasers.

Movaco's six Spanish facilities offer direct, accessible service with their specialized sales network, and after-sales technical support for all of their products and services. The company has been ISO 9002 certified since 2000 and was re-certified for ISO 9001:2008 in 2009. Since December 2016 Movaco is certified by the new ISO 9001:2015 standard. The company also holds ISO 14001:2004 environmental management certification, as well as OHSAS 18001:2007 management system certification. Movaco received its wholesale distribution license in August 2015, as well as its GDP (good distribution practice) certificate.

The company's mission and commitment to quality and stakeholder involvement are outlined in its quality policy statement.

Grif_ls supports the Canadian Blood Services' Missing Type CampaignGrif_ls is proud to support the Canadian Blood Services' Missing Type Campaign. This is a global campaign whose goal is to increase the number of new registered blood donors. In the last decade there has been a downward trend of new registered blood donors, which may put the blood supply at risk + info

Grifols´ turnover increased by 7.1% in the first nine months of 2010 to 738.8 MMGrifols reaches its highest quarterly turnover, exceeding 251 million Euros between July and September 2010. In the third quarter, the Bioscience division grew by 14.6% mainly driven by the U.S. market. The higher sale volumes of plasma derivatives such as albumin and IVIG, with double-digit increases, confirm the upward trend of the sector. Recurrent EBITDA of the business grew by 2.5% up to 212.1 million Euros. Net profit, at 97.0 million Euros, falls by 17.1% due to costs associated with the corporate transaction and higher financial expenses. + info

Grifols to develop Fundació Clínic device designed to increase the viability of livers for transplant· The device, which has been patented by Fundació Clínic, will be manufactured and marketed by Grifols. It is based on the principle of preserving livers for transplant in conditions which are similar to those inside the body (as against the cold storage methods currently used) and this should significantly increase the number of viable livers available for transplant. · The licensing and cooperation agreement signed between the two companies provides a basis for adapting the device for human use and taking it to clinical trial to validate its use. + info

Grifols to acquire Talecris Biotherapeutics creating a world leading provider of life-saving plasma protein therapiesThe combination of Grifols and Talecris will create a diversified, global provider of life-saving and life enhancing plasma protein therapeutics built on the strong global presence of Grifols and the established position of Talecris in the United States and Canada. The merger accelerates key strategic initiatives for both Talecris and Grifols as it creates a more efficient platform for manufacturing, innovation and global sales and marketing. Combining the expertise of both companies will build upon their individual legacies of patient commitment, growth and innovation while increasing the availability of high quality plasma protein therapies for patients worldwide. + info

Grifols launches Niuliva®Grifols has launched of Niuliva® 250 IU/ml, its human anti-hepatitis B immunoglobulin for intravenous administration, in Spain and Italy. The manufacturing process of Niuliva® produces a high purity, pasteurized solution with a high titer of specific anti-hepatitis B antibodies. + info

Grifols Academy of Plasmapheresis opens in USBased in Arizona in the United States, the initiative reflects a firm commitment to employee training and knowledge sharing in line with the degree of specialisation required in the plasma derivative industry + info

Grifols gets a minority stake in Cardio3 BioSciencesFounded by a group of scientists from the Cardiovascular Center in Aalst, Belgium on a technology developed by researchers at Mayo Clinic, Cardio3 BioSciences specialises in stem-cell based biotherapeutic R&D for the treatment of cardiovascular diseases. + info

Grifols acquires office complex in Sant CugatThe new complex will allow the Grifols group to centralize its shared corporate areas, while also providing space for future growth. These areas are currently based in rented office space, primarily in Barcelona, and without any scope for physical expansion. + info